Carboplatin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
CARBOPLATIN: From Ovarian Cancer to Female Breast Carcinoma
One-Sentence Summary
Carboplatin is a platinum-based alkylating chemotherapy agent, most widely recognized as a first-line treatment backbone for ovarian cancer and other platinum-sensitive malignancies. The TxGNN model predicts it may be effective for Female Breast Carcinoma—especially triple-negative (TNBC) and BRCA-mutated subtypes— with 50 clinical trials and 20 publications retrieved in support of this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current regulatory database |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L2 |
| US Market Status | Not found in regulatory database (likely a data gap) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the DrugBank query in this evidence pack. Based on established pharmacology, carboplatin is a second-generation platinum coordination compound that forms covalent DNA adducts—primarily intrastrand (Pt-GG) and interstrand cross-links—blocking DNA replication and transcription. Cells with impaired DNA repair mechanisms accumulate lethal damage and are driven toward apoptosis.
Triple-negative breast cancer (TNBC) and BRCA1/2-mutated breast cancers harbor homologous recombination deficiency (HRD), rendering them exquisitely sensitive to DNA cross-linking agents such as carboplatin. When homologous recombination cannot repair double-strand breaks, tumor cells cannot recover from carboplatin-induced damage. This rationale is supported by GeparSixto (Lancet Oncol, 2014), a landmark randomized Phase 2 trial demonstrating that carboplatin significantly improved pathological complete response (pCR) in TNBC (53.2% vs. 36.9%). A 2022 individual participant data meta-analysis (PMID 35462344) further confirmed that adding carboplatin to neoadjuvant/adjuvant chemotherapy improves overall survival in TNBC.
For HER2-positive breast cancer, carboplatin combined with trastuzumab and pertuzumab (the TCHP regimen) demonstrates synergistic anti-tumor activity, with a completed Phase 3 trial (NCT02003209, n=315) specifically evaluating this approach. An ongoing Phase 3 TNBC trial (NCT03168880, n=720) and an additional recruiting study (NCT04159142, n=414) are expected to further consolidate the evidence base and may ultimately upgrade the evidence level to L1.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03168880 | Phase 3 | Active, Not Recruiting | 720 | RCT comparing weekly paclitaxel alone vs. weekly paclitaxel + carboplatin as neoadjuvant therapy in patients with large operable or locally advanced TNBC |
| NCT02003209 | Phase 3 | Completed | 315 | RCT evaluating TCHP (docetaxel + carboplatin + trastuzumab + pertuzumab) ± estrogen deprivation in HR+/HER2+ locally advanced breast cancer; primary endpoint: pCR rate |
| NCT00532727 | Phase 3 | Unknown | 400 | RCT directly comparing carboplatin vs. docetaxel as standard of care for metastatic or recurrent TNBC |
| NCT04159142 | Phase 2 | Recruiting | 414 | Multicenter RCT comparing nab-paclitaxel + carboplatin vs. nab-paclitaxel + capecitabine in advanced TNBC |
| NCT02413320 | Phase 2 | Completed | 101 | Randomized Phase 2 evaluating carboplatin + docetaxel vs. carboplatin + paclitaxel as neoadjuvant therapy in Stage I–III TNBC |
| NCT00232505 | Phase 2 | Completed | 112 | Randomized Phase 2 comparing cetuximab alone vs. cetuximab + carboplatin in metastatic ER−/PR−/HER2− breast cancer |
| NCT00003612 | Phase 2 | Completed | 92 | Randomized Phase 2 of paclitaxel + carboplatin + trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer |
| NCT00005963 | Phase 2 | Completed | 53 | Phase 2 study of docetaxel + carboplatin as first-line chemotherapy for metastatic breast cancer |
| NCT07103447 | Phase 2 | Not Yet Recruiting | 54 | Prospective multicenter study of AK112 (bispecific anti-PD-1/VEGF antibody) + albumin-bound paclitaxel + carboplatin as neoadjuvant therapy for TNBC |
| NCT02418624 | Phase 1 | Completed | 25 | Dose-finding study of carboplatin + olaparib (PARP inhibitor) in BRCA1/2-mutated, HER2-negative advanced breast cancer; explores platinum–PARP inhibitor synergy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33208340 | 2021 | RCT | Clin Cancer Res | NeoSTOP: Randomized Phase 2 comparing anthracycline-free (carboplatin + taxane) vs. anthracycline-containing carboplatin regimen in Stage I–III TNBC; evaluates pCR across both arms |
| 24794243 | 2014 | RCT | Lancet Oncol | GeparSixto: Addition of carboplatin to neoadjuvant therapy significantly improved pCR in TNBC (53.2% vs. 36.9%; p=0.005); landmark evidence establishing carboplatin’s role in TNBC |
| 39671272 | 2025 | RCT | JAMA | CamRelief: Phase 3 RCT showing camrelizumab (anti-PD-1) combined with platinum-containing neoadjuvant chemotherapy improves outcomes in early/locally advanced TNBC |
| 40593759 | 2025 | RCT | Nat Commun | MUKDEN 06: ARX788 (anti-HER2 ADC) + pyrotinib vs. TCbHP (docetaxel + carboplatin + trastuzumab + pertuzumab) in neoadjuvant HER2+ breast cancer; establishes TCbHP as the standard comparator |
| 40468999 | 2025 | RCT | Acta Oncol | TCHL 5-year follow-up: TCH (docetaxel + carboplatin + trastuzumab) vs. TCHL in HER2+ neoadjuvant breast cancer with long-term efficacy and serum biomarker analysis |
| 38309017 | 2024 | RCT | Eur J Cancer | BROCADE3 final OS results: Adding veliparib to carboplatin + paclitaxel significantly improved PFS in germline BRCA1/2-mutated, HER2-negative advanced breast cancer |
| 35462344 | 2022 | Meta-analysis | Breast | Individual participant data meta-analysis confirming carboplatin addition to neoadjuvant/adjuvant chemotherapy improves overall survival in TNBC |
| 40817986 | 2025 | RCT | Breast Cancer Res Treat | Randomized Phase 2 comparing single-agent carboplatin vs. carboplatin + everolimus (mTOR inhibitor) in advanced TNBC; investigates mTOR pathway-mediated platinum sensitization |
| 33256829 | 2020 | Phase 2 | Breast Cancer Res | Phase 2 study of bevacizumab + carboplatin in breast cancer brain metastases; assessed intracranial response rate and safety |
| 16720915 | 2006 | Review | Med Oncol | Comprehensive review of preclinical and clinical evidence for paclitaxel-carboplatin synergy, efficacy, and safety in advanced breast cancer |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Platinum-based alkylating agent) |
| Myelosuppression Risk | High — thrombocytopenia is the dose-limiting toxicity; neutropenia and anemia are also common at therapeutic doses |
| Emetogenicity Classification | Moderate to High (moderately emetogenic at standard doses; highly emetogenic at high doses used in stem-cell transplant conditioning) |
| Monitoring Items | CBC with differential and platelet count before each cycle; serum creatinine and estimated creatinine clearance for Calvert formula dose calculation; audiometry if high-dose regimen; electrolytes (Ca²⁺, Mg²⁺, K⁺) |
| Handling Protection | Must follow cytotoxic drug handling regulations; prepare in a biological safety cabinet with closed-system transfer devices; appropriate PPE required throughout preparation and administration |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple randomized Phase 2 and Phase 3 clinical trials, alongside a meta-analysis confirming overall survival benefit, establish carboplatin as a well-supported therapy for female breast carcinoma—particularly TNBC (driven by HRD/BRCA-mediated platinum sensitivity) and HER2-positive subtypes (TCH/TCHP regimens). The mechanistic and clinical evidence base is robust, and carboplatin is already embedded in internationally recognized breast cancer protocols.
To proceed, the following is needed:
- Verification of US FDA regulatory approval status — the current database shows 0 registered NDAs, which almost certainly reflects a data gap rather than absence of approval
- Detailed mechanism of action (MOA) data from DrugBank API (currently missing from this evidence pack)
- Patient stratification plan by breast cancer subtype: prioritize TNBC with confirmed HRD/BRCA mutation and HER2-positive disease for the strongest benefit-risk profile
- Safety monitoring protocol addressing thrombocytopenia (dose-limiting), renal function surveillance for Calvert formula dosing, and audiometry for high-dose regimens
- Tracking of results from ongoing Phase 3 trials (NCT03168880, n=720 and NCT04159142, n=414), whose completion is expected to upgrade the evidence level from L2 to L1
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.